Gastrointestinal Stromal Tumors of the Distal Gastrointestinal Tract

Katherine A. Kelley; Raphael Byrne; Kim C. Lu

doi:10.1055/s-0038-1642053

Clinics in Colon and Rectal Surgery, Inhaltsverzeichnis

Clin Colon Rectal Surg 2018; 31(05): 295-300
DOI: 10.1055/s-0038-1642053

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Gastrointestinal Stromal Tumors of the Distal Gastrointestinal Tract

Autoren

Katherine A. Kelley

¹Division of Gastrointestinal and General Surgery, Department of Surgery, Oregon Health & Science University, Portland, Oregon
Raphael Byrne

¹Division of Gastrointestinal and General Surgery, Department of Surgery, Oregon Health & Science University, Portland, Oregon
Kim C. Lu

¹Division of Gastrointestinal and General Surgery, Department of Surgery, Oregon Health & Science University, Portland, Oregon

Abstract

Gastrointestinal stromal tumors (GISTs) are rare in occurrence, but comprise the most common mesenchymal tumors of the gastrointestinal tract and affect between 15 and 20 individuals per million per year. Due to recent advancements in molecular classification of these tumors, medical therapy has provided improved outcomes to a historically surgically managed disease. This review article briefly discusses the molecular characteristics, medical and surgical therapies, and future of GIST management.

Keywords

gastrointestinal stromal tumors - mesenchymal tumors - GIST management

Volltext

Referenzen

References
1 Crosby JA, Catton CN, Davis A. , et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8 (01) 50-59
2 DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231 (01) 51-58
3 Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg 1996; 33 (10) 817-872
4 Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15 (04) 1293-1301
5 Raut CP, DeMatteo RP. Prognostic factors for primary GIST: prime time for personalized therapy?. Ann Surg Oncol 2008; 15 (01) 4-6
6 Raut CP. Current Surgical Therapy, 11th ed. Philadelphia: Saunders; 2013: 96-103
7 Scarpa M, Bertin M, Ruffolo C, Polese L, D'Amico DF, Angriman I. A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol 2008; 98 (05) 384-392
8 Hirota S, Isozaki K, Moriyama Y. , et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279 (5350): 577-580
9 Reichardt P, Hogendoorn PC, Tamborini E. , et al. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol 2009; 36 (04) 290-301
10 Heinrich MC, Corless CL, Duensing A. , et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299 (5607): 708-710
11 Mason EF, Hornick JL. Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis. Mod Pathol 2013; 26 (11) 1492-1497
12 Janeway KA, Kim SY, Lodish M. , et al; NIH Pediatric and Wild-Type GIST Clinic. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011; 108 (01) 314-318
13 Demetri GD, Benjamin RS, Blanke CD. , et al; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 (Suppl. 02) S1-S29 , quiz S30
14 Miranda C, Nucifora M, Molinari F. , et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18 (06) 1769-1776
15 Agaram NP, Wong GC, Guo T. , et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008; 47 (10) 853-859
16 Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 2009; 266 (01) 43-52
17 Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11 (08) 728-734
18 Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 13 (10) 1134-1142
19 Espinosa I, Lee CH, Kim MK. , et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008; 32 (02) 210-218
20 Zhao WY, Xu J, Wang M. , et al. Prognostic value of Ki67 index in gastrointestinal stromal tumors. Int J Clin Exp Pathol 2014; 7 (05) 2298-2304
21 Nilsson B, Bümming P, Meis-Kindblom JM. , et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005; 103 (04) 821-829
22 Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38 (Suppl. 05) S37-S38
23 Bauer S, Corless CL, Heinrich MC. , et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003; 51 (03) 261-265
24 Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23 (02) 70-83
25 Raut CP, Morgan JA, Ashley SW. Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease. Curr Opin Gastroenterol 2007; 23 (02) 149-158
26 Stroszczynski C, Jost D, Reichardt P. , et al. Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI. Eur Radiol 2005; 15 (12) 2448-2456
27 Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004; 25 (05) 433-438
28 Changchien CR, Wu MC, Tasi WS. , et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum 2004; 47 (11) 1922-1929
29 Nguyen SQ, Divino CM, Wang JL, Dikman SH. Laparoscopic management of gastrointestinal stromal tumors. Surg Endosc 2006; 20 (05) 713-716
30 McCarter MD, Antonescu CR, Ballman KV. , et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant Gist Study Team. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg 2012; 215 (01) 53-59 , discussion 59–60
31 Druker BJ, Talpaz M, Resta DJ. , et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 (14) 1031-1037
32 van Oosterom AT, Judson I, Verweij J. , et al; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358 (9291): 1421-1423
33 Demetri GD, von Mehren M, Blanke CD. , et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (07) 472-480
34 Verweij J, Casali PG, Zalcberg J. , et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364 (9440): 1127-1134
35 Blanke CD, Rankin C, Demetri GD. , et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26 (04) 626-632
36 Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28 (07) 1247-1253
37 Lee CK, Goldstein D, Gibbs E. , et al. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. Eur J Cancer 2015; 51 (07) 852-860
38 Joensuu H, Vehtari A, Riihimäki J. , et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13 (03) 265-274
39 Fletcher CD, Berman JJ, Corless C. , et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33 (05) 459-465
40 Rutkowski P, Bylina E, Wozniak A. , et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011; 37 (10) 890-896
41 DeMatteo RP, Ballman KV, Antonescu CR. , et al. Placebo-controlled randomized trial of adjuvant imatinib mesylate following the resection of localized, primary gastrointestinal stromal tumor (GIST). Lancet 2009; 373 (9669): 1097-1104
42 Casali PG, Le Cesne A, Poveda Velasco A. , et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 2015; 33 (36) 4276-4283
43 Eisenberg BL, Harris J, Blanke CD. , et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99 (01) 42-47
44 Wilkinson MJ, Fitzgerald JE, Strauss DC. , et al. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib. Br J Surg 2015; 102 (08) 965-971
45 Bauer S, Rutkowski P, Hohenberger P. , et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 2014; 40 (04) 412-419
46 DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245 (03) 347-352
47 Zhan WH, Wang PZ, Shao YF. , et al. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]. Chin J Gastrointestinal Surg 2006; 9 (05) 383-387
48 DeMatteo RP, Ballman KV, Antonescu CR. , et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg 2013; 258 (03) 422-429
49 Kang YK, Ryu MH, Yoo C. , et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013; 14 (12) 1175-1182
50 Corless CL, Ballman KV, Antonescu CR. , et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.. J Clin Oncol 2014; 32 (15) 1563-1570